Lorvotuzumab mertansine
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD56 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
1008106-64-6  |
| ChemSpider | none |
| UNII |
0IVD6ASY0W |
| KEGG |
D09927 |
 (what is this?) (verify) | |
Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP. (When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine.)
Lorvotuzumab mertansine is an experimental agent created for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer).[1][2]
It has been granted Orphan drug status for Merkel cell carcinoma.[3]
It has reported encouraging Phase II results for small-cell lung cancer.[4]
References
- ↑ Dimond (9 Mar 2010). "Antibody-Drug Conjugates Stage a Comeback".
- ↑ ImmunoGen reports encouraging clinical data of IMGN901. News-medical.net. Retrieved on 2010-11-20.
- ↑ http://www.news-medical.net/news/20100308/ImmunoGen-receives-FDA-orphan-drug-designation-for-IMGN901-compound-in-treatment-of-MCC.aspx
- ↑ "ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer". 2009.
This article is issued from Wikipedia - version of the 9/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.